To Evaluate and Assess Shoulder Morbidity using Constant Murley score after Neck Dissection in Oral Cancer Patients- A Prospective Observational Study. - NIL

开始日期2025-05-05

申办/合作机构

Advanced Centre for Treatment Research & Education in Cancer

CTRI/2024/06/069213 / Not yet recruitingN/A

Late Mortality, Burden of Morbidity and Quality of Life in Long Term Survivors of Hematopoietic Cell Transplantation: Experience from A Single Centre in India - NIL

开始日期2024-07-02

申办/合作机构

Advanced Centre for Treatment Research & Education in Cancer

CTRI/2024/04/066154 / Not yet recruitingN/A

Retrospective Analysis of Outcome and Survival of Patients with Multiple Myeloma who Relapse post Autologous Stem Cell Transplant - NIL

开始日期2024-05-07

申办/合作机构

Advanced Centre for Treatment Research & Education in Cancer

100 项与 Advanced Centre for Treatment Research & Education in Cancer 相关的临床结果

登录后查看更多信息

0 项与 Advanced Centre for Treatment Research & Education in Cancer 相关的专利（医药）

登录后查看更多信息

224

项与 Advanced Centre for Treatment Research & Education in Cancer 相关的文献（医药）

2024-12-01·European Journal of Surgical Oncology

Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review

Review

作者: Solanki, Sohan Lal ; Bhatt, Aditi ; Kuberkar, Deepali V ; Gangakhedkar, Gauri ; Kuberkar, Deepali V. ; Salunke, Bindiya ; Ambulkar, Reshma

The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.

2024-10-01·The Lancet Regional Health - Southeast Asia

Drug development in LMICs: could the emerging Indian model usher the southeast Asian region?

Review

作者: Pant, Bharat ; Goda, Jayant ; Gota, Vikram

Low-income and middle-income countries (LMICs) of southeast Asia are passing through a similar phase as India in their tryst with the development of novel drugs. They are beginning to break away from their dependency on the institutions of our developed world. Over the past few years, Tata Memorial Centre-India's premier cancer centre-has shown the tenacity to develop drugs within the national frontiers. By collaborating with the domestic pharmaceutical industries, it has been able to have a steady pipeline of drugs under development, with two of them receiving marketing authorization recently. Lately, Indonesia and Vietnam have also shown an inclination towards public-private partnerships for similar motives. However, due to prolonged innovative stagnation, the entire drug development machinery faces challenges stretching all the way from arranging funds to persuading regulatory bodies. In this Viewpoint, we have tried to address a few of those issues and their potential solutions, with the intention to share our own experience which might be useful to other LMICs in connecting some adamant dots.

2024-09-09·Brachytherapy

Gynecological brachytherapy hybrid training: The Tata Memorial Centre and BrachyAcademy experience.

Article

作者: Kohle, Satish ; Dizendorf, Elena ; Chargari, Cyrus ; Bhajbhuje, Rajesh ; Mittal, Prachi ; Nout, Remi ; Chopra, Supriya ; Upreti, Ritu Raj ; Panda, Subhajit ; Tanderup, Kari ; Gupta, Ankita ; Jeeva, Meenakshi ; Bhavke, Akshay ; Ghadi, Yogesh ; Sturdza, Alina ; Tatli, Hamza ; Agarwal, Jai Prakash ; Jain, Jeevanshu ; Tharavichitkul, Ekkasit

PURPOSEThe lack of training is a significant barrier to practicing brachytherapy (BT). Tata Memorial Centre, alongside international BT experts and BrachyAcademy, developed a hybrid gynecological BT training module. This study outlines the preparation, organization, and execution of the 2022-2023 Mumbai training, evaluates its effectiveness, and highlights areas for improvement.MATERIALS AND METHODSParticipants were radiation oncologists (RO) and medical physicists (MP) with experience in gynecological BT aiming to transition to image-guided brachytherapy (IGBT). The training covered cervical, endometrial, vaginal, vulvar, periurethral cancers, and pelvic reirradiation. The hybrid course included online pre and postcourse homework assignments, a live workshop with hands-on training, a 6-month online follow-up, and a 12-month opportunity to share the transition experience.RESULTSThe December 2022 Mumbai live workshop spanned 2.5 days, attracting 39 participants from 8 countries (Asia, Africa, Australia/Oceania). Feedback rated the course 9/10, with 78% fully meeting expectations. Forty-four percent suggested extending hands-on training. At the 6-month follow-up, response rates were low (33% RO, 11% MP). Among responding RO, 70% reported practice changes after attending the course, 40% implemented IGBT concepts in clinical practice, and 50% increased confidence in image-guided procedures. Overall, 45% of respondent sites could strengthen their intracavitary/interstitial program, while others faced limitations due to lack of access to advanced BT applicators.CONCLUSIONThe hybrid gynecological BT training concept was successfully executed. Areas for improvement include extending hands-on training and enhancing participant engagement postcourse. Structured steps beyond training may be needed to improve the utilization of advanced brachytherapy for gynecological cancers.

100 项与 Advanced Centre for Treatment Research & Education in Cancer 相关的药物交易

登录后查看更多信息

100 项与 Advanced Centre for Treatment Research & Education in Cancer 相关的转化医学

登录后查看更多信息